New initiatives, faster Sputnik rollout can lift DRL
Synopsis
Revenues rose 12% and net profit declined by a percent over the prior year. Ebitda margin dropped 560 bps to 20.7%. The disappointing performance was caused by underperformance of the US and API businesses. Profitability was impacted due to price erosion, increase in inventory provisions related to few products and higher other expenditure.
ET Intelligence Group: The June-quarter performance of drug major Dr Reddy’s Labs (DRL) turned out to be a washout for the Street. What aggravated matters further was the company getting a subpoena from the US market regulator to furnish documents on certain CIS geographies in relation to the complaint that alleged payments to healthcare professionals in violation of US anti-corruption laws were made.
This caused the DRL stock to slump more
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Get Offer
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.